Participants 116 153 6
sentinel lymph node-positive patients
Participants 446 526 5
patients with sentinel lymph node-positive (SLN+) primary invasive breast cancer
Participants 884 917 3
patients with SLN+ breast cancer.
Participants 939 979 6
Patients with SLN+ primary breast cancer
Participants 1287 1304 7
474 SLN+ patients
Participants 1529 1601 3
patients were premenopausal (34% vs. 27%; P = .095) and had pT2-3 tumors
Participants 1722 1825 3
patients with known human epidermal growth factor receptor type 2 positive tumor (12% vs. 17%, P = .066
Participants 2359 2421 3
premenopausal patients and patients with larger (pT2-3) tumors
